COMPANY
Kuria Therapeutics, Inc.
NIH awards 2
- NIH award 1R43EY038532-01 FY2026: $306,805 awarded for that fiscal year; activity R43 (SBIR); PI STEVENS, MISTY WARD; recipient as written: KURIA THERAPEUTICS, INC, LITTLE ROCK, AR. Testing of SCO-116, an NRF2 activa source ↗
- NIH award 1R44EY038121-01 FY2025: $399,865 awarded for that fiscal year; activity R44 (SBIR); PI WARD, KEITH W; recipient as written: KURIA THERAPEUTICS, INC, LITTLE ROCK, AR. IND-enabling studies of KTX-1161, a nove source ↗
Funding and NIH signals
- NIH award NIH awarded $307K (SBIR Phase I 1R43EY038532-01, new, notice Sep 2, 2026). NIH RePORTER 1R43EY038532-01 (Sep 2, 2026)
Evidence (1 event)
- Sep 2, 2026 · NIH RePORTER 1R43EY038532-01
Organization: KURIA THERAPEUTICS, INC; City/State: LITTLE ROCK, AR; Project number: 1R43EY038532-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 306805; Administering IC: National Eye Institute; Project title: Testing of SCO-116, an NRF2 activator for Fuchs' Dystrophy, in cultured human corneas; Organization type: Domestic For-Profits
- Sep 2, 2026 · NIH RePORTER 1R43EY038532-01